Retraction of the landmark glyphosate safety publication by Williams, Kroes and Munro (2000) should be reversed.
Письмо в редакциюНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Borgert Christopher J, Abdollahi Mohammad, Ansell Jay M, Aschner Michael, Bates Christopher A, Berry Sir Colin, Bolon Brad, Boogaard Peter J, Budinksy Robert A, Burgoon Lyle D, Burin Gary, Bus James S, Clewell Harvey, Cohen Samuel M, Colnot Thomas, Darby Paul S, Dekant Wolfgang, DeSesso John, Dietrich Daniel R, Djukic Mirjana, Docea Anca Oana, Domingo Jose L, Eaton David L, Engelhardt Jeffery A, Fairbrother Anne, Felsot Allan, Fenner-Crisp Penelope A, Gentry Robinan, Goodman Jay I, Gori Gio B, Greim Helmut, Heslop-Harrison J S, Hengstler Jan G, Jaeschke Hartmut, Kaminski Norbert E, Kacew Sam, Kim James, Kiorpes Anthony L, Klaassen Curtis, Klaunig James E, Loccisano Anne, MacDonald James S, Mally Angela, Marquardt Hans W J, Marty M Sue, Matthews John C, McClellan Roger O, Meeks Robert G, Millner Glenn C, Pariza Michael W, Paustenbach Dennis, Pelkonen Olavi, Sarvadi David, Savolainen Kai, Simon Ted W, Smith Carr J, Solomon Keith R, Tarka Stanley M, Tsatsakis Aristidis M, Tsuji Joyce, Vermeulen Nico P E, Wallace Kendall B, Wernke Michael, Williams Jonathan P, Witorsch Raphael J, Yamazaki Hiroshi
Аннотация
The decision by the co-Editor-in-Chief of Regulatory Toxicology and Pharmacology, Prof. Martin van den Berg, to retract the 2000 review article by Williams, Kroes, and Munro has elicited widespread criticism within the scientific community. Issued in late 2025, the retraction decision cites procedural concerns including potential ghostwriting, undisclosed conflicts of interest, and omission of certain unpublished studies, invoking Committee on Publication Ethics guidelines despite lacking evidence of fraud or scientific flaws. This editorial argues that the retraction decision involves editorial overreach and misapplication of the guidelines. The alleged omissions stemmed from proprietary data access limitations that were disclosed in the original paper. Subsequent reviews by several independent expert panels and regulatory authorities with access to all glyphosate data, including the studies cited by the retracting editor, reached similar conclusions. Claims of ghostwriting were previously investigated and found lacking, including a declaration by EFSA as to the clarity of the conflict disclosures. The retraction's timing, reliance on litigation documents, and apparent biases that were not disclosed in the retraction notice raise questions of ideological interference. Absent substantive rebuttals based on scientific merit rather than speculative claims of inappropriate authorship and data access, this retraction decision sets a dangerous precedent for retroactive censorship, potentially chilling beneficial industry-academic collaborations and eroding trust in the integrity of scientific publishing. With the strongest conviction, we assert that retracting a paper without scientific flaws isn't protection-it is censorship. We therefore call for the immediate reversal of this flawed and unjustified retraction to preserve trust in peer-reviewed literature.